logo
These clever birds can open trash cans and drink from water fountains

These clever birds can open trash cans and drink from water fountains

CNNa day ago

First, these parrots learned to open trash cans to forage for food. Now, they've taken it a step further – and have figured out how to turn on water fountains for a sip along with their meal.
These are Australia's iconic sulphur-crested cockatoos – white birds with a yellow tuft on their heads, known for their loud, grating screech. But they're also incredibly intelligent, with large brains and nimble feet that have allowed them to pick up new habits in urban environments.
The cockatoos in western Sydney, in particular, caught scientists' attention with their latest trick of drinking from public fountains. After researchers first noticed this phenomenon in 2018, they tagged 24 birds and set up cameras near fountains in the area – then sat back and watched.
Throughout two months in the fall of 2019, they recorded most of the tagged birds attempting to drink from the fountains. Also known as bubblers, these fountains are operated by a twist handle – easy enough for a person to operate, but complex for an animal to figure out.
Yet, the cockatoos did. They used different techniques: some would stand with both feet on the handle, while others would put one foot on the handle and one foot on the rubber spout. Then, they'd lower their body weight to turn the handle clockwise – holding the handle in place while twisting their head to take a drink.
They weren't always successful – it worked about half the time, and five of the 10 drinking fountains in the area had 'chew marks' indicating cockatoos had been there before. But the success rate also meant that the cockatoos had likely been doing this for some time, said the researchers in their study, published Wednesday in the journal Biology Letters.
The team had studied Sydney's sulphur-crested cockatoos before; in 2021, they published another paper examining the birds' newly observed ability to lift closed trash bin lids with their beaks and feet to access the food inside.
These innovative behaviors aren't just animals being amusing or clever – they show the birds' ability to adapt to urban environments, and the power of social learning among animals, the researchers said.
'We know parrots like cockatoos are amongst the smartest birds out there, and the fact they're so social – so they have the opportunity to learn from one another if a new behavior does pop up, if one genius bird does invent something,' said one of the study's co-authors, Lucy M. Aplin, an associate professor at the Australian National University, in an interview with CNN affiliate ABC Radio.
There are some questions still unanswered. The researchers don't know why exactly the cockatoos are flocking to drinking fountains, instead of other easily accessible natural water sources in the area. At first they thought the fountains might be a backup option on especially hot days when local creeks run dry – but that wasn't the case.
Other theories are that the birds feel safer drinking from fountains in public areas where there are fewer predators, or that they simply prefer the taste of fountain water – but that would need further study to determine.
Now, the researchers want to know what else cockatoos can do – and any habits they may have already developed that just haven't been studied yet.
'We've had some really interesting innovations reported to us, and some examples include unzipping school backpacks and stealing school lunches,' Aplin told ABC Radio. 'It has become such a problem in some areas that they have to bring the school bags into the classroom rather than leaving them outside!'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Add-On D-Serine Shows Promise in Severe Depression
Add-On D-Serine Shows Promise in Severe Depression

Medscape

timean hour ago

  • Medscape

Add-On D-Serine Shows Promise in Severe Depression

D-serine as an adjunctive treatment did not outperform placebo overall in patients with major depressive disorder (MDD), a new trial showed. However, depressive symptoms and anhedonia were significantly alleviated among patients with severe MDD, particularly among those on higher doses of standard medications. METHODOLOGY: Researchers conducted a 6-week, randomised, double-blind, placebo-controlled trial including 44 adult inpatients (mean age, 43.55 years; 45% women) diagnosed with moderate to severe MDD from Basel, Switzerland. Participants were randomly assigned in a 1:1 ratio to receive either D-serine (2 g/d) or placebo alongside standard treatment. The primary outcome was the change in clinician-rated depressive symptoms from baseline to post-intervention, measured using the 17-item Hamilton Depression Rating Scale. Secondary outcomes were self-reported depressive symptoms, anxiety, and anhedonia, measured using the Beck Depression Inventory-II, State-Trait Anxiety Inventory-1, and Snaith-Hamilton Pleasure Scale, respectively. TAKEAWAY: Both D-serine and placebo groups showed a significant reduction in symptoms across all measures, with no significant differences observed in the overall sample. In the subgroup analysis, D-serine significantly alleviated depressive symptoms in participants with severe MDD ( P = .02), with a trend towards reduction in anhedonia. = .02), with a trend towards reduction in anhedonia. In the D-serine group, clinical improvements were correlated with higher baseline depression severity and higher doses of standard medication. No serious adverse events were reported. IN PRACTICE: "DS [D-serine] may offer therapeutic benefits for patients with severe MDD, particularly when used alongside greater doses of TAU [treatment as usual] medication. These findings support the potential of DS as a synergistic adjunctive strategy to enhance the therapeutic effect of pharmacological interventions, especially in severe cases," the authors wrote. SOURCE: This study was led by Lukas Sempach, University of Basel, Basel, Switzerland. It was published online on May 26 in the Journal of Affective Disorders . LIMITATIONS: The small sample size limited the study's generalisability and reduced its power to detect small to moderate treatment effects, particularly in patients with severe depression. Additionally, the relatively low dose of D-serine used, along with its metabolism, may have limited its engagement with N-methyl-D-aspartate receptors. DISCLOSURES: This study was supported by the Gertrud Thalmann Foundation of the University Psychiatric Clinics Basel and the Stiftung zur Förderung der gastroenterologischen und allgemeinen klinischen Forschung sowie der medizinischen Bildauswertung. The authors reported having no conflicts of interest.

MRI-Led Surveillance Stratifies Prostate Cancer Risk
MRI-Led Surveillance Stratifies Prostate Cancer Risk

Medscape

timean hour ago

  • Medscape

MRI-Led Surveillance Stratifies Prostate Cancer Risk

In a cohort study of patients with prostate cancer, MRI-led risk-adapted active surveillance demonstrated effectiveness in risk stratification. The approach showed that MRI visibility and the presence of secondary Gleason pattern 4 at baseline were associated with higher rates of progression and treatment initiation. METHODOLOGY: Researchers analysed 1150 patients who started active surveillance between February 2000 and July 2023, including those with a Gleason score (GS) ≤ 3 + 4, prostate-specific antigen (PSA) < 20 ng/mL, and at least two MRI scans. Participants underwent PSA testing three to four times in the first year, followed by biannual testing; MRI was performed at baseline and 12 months, with an additional MRI scan performed at 24 months for those with MRI-visible lesions at baseline. Patients were stratified into four groups on the basis of baseline risk factors, including GS (3 + 3 vs 3 + 4) and MRI visibility ("non-visible disease" vs "visible disease"). The primary outcome was event-free survival, with an event defined as the detection of GS ≥ 4 + 3 or the initiation of any prostate cancer treatment. The median follow-up duration was 64 months per person overall and 72 months for 732 patients without an event. At baseline, 64% of patients had GS 3 + 3 and 36% had GS 3 + 4; 49% of those with GS 3 + 4 had MRI-visible disease. TAKEAWAY: Event-free survival rates varied significantly on the basis of the risk group, with 5-year rates of 91% for non-visible GS 3 + 3, 71% for MRI-visible GS 3 + 3, 71% for non-visible GS 3 + 4, and 44% for MRI-visible GS 3 + 4 disease. Among 487 patients who underwent follow-up biopsies, histological upgrade to GS ≥ 4 + 3 occurred in 67 patients; non-visible GS 3 + 3 cases had 5- and 10-year rates of 1.2% and 6.1%, respectively, for histological progression to GS ≥ 4 + 3, while the rates were 17% and 43% for those with MRI-visible GS 3 + 4 disease at baseline, respectively. Progression to nodal or bone metastases was observed in 10 patients, occurring only in those who had declined recommended follow-up MRI and/or biopsies. The 10-year rate of commencing treatment was 28% for those with non-visible GS 3 + 3 disease vs 85% for those with MRI-visible GS 3 + 4 disease and 46% for those with non-visible GS 3 + 4 disease vs 54% for those with MRI-visible GS 3 + 3 disease. IN PRACTICE: "Results from our cohort suggest that AS [active surveillance] patients can be monitored safely with MRI, and the decision to biopsy was based on MRI findings and PSA changes. Prospective, multicentre, clinical trials are required and currently being designed to further evaluate this approach," the authors wrote. SOURCE: This study was led by Cameron Englman, Division of Surgery & Interventional Science, University College London, London, England. It was published online on May 27, 2025, in European Urology . LIMITATIONS: Compared with time-based biopsy protocols, the MRI-led risk-adapted approach may underestimate histological progression. Additionally, as a cohort study without a strict protocol, practice evolved alongside contemporary pathology and radiology standards, with MRI quality, reporting standards, and the definition of radiological progression varying over time, particularly improving after the adoption of the PRECISE recommendations in 2016. DISCLOSURES: This study did not receive any specific funding. Several authors reported receiving consulting fees and grants and having other ties with various sources.

‘Enormous Burden' Cataloged in Relapsing Polychondritis
‘Enormous Burden' Cataloged in Relapsing Polychondritis

Medscape

time3 hours ago

  • Medscape

‘Enormous Burden' Cataloged in Relapsing Polychondritis

A large multicenter prospective cohort study has expanded 'the understanding of the range of manifestations of disease in patients with relapsing polychondritis [RP]' — particularly involving the ear, nose, throat, and musculoskeletal systems — as well as a high prevalence of organ damage, near-universal use of glucocorticoids, and frequent use of additional nonbiologic or biologic immunomodulatory therapies. METHODOLOGY: Researchers conducted a multicenter cohort study between 2017 and 2023 to evaluate clinical manifestations, treatment approaches, and the association between them in 195 patients with RP (median age, 48 years; 85.6% women). A diagnosis of RP was confirmed using comprehensive laboratory, radiographic, and other tests; all participants tested negative for proteinase 3 and myeloperoxidase. Data on clinical manifestations, organ damage, and medication history were collected at baseline study visits using standardized case report forms. Patients were grouped by treatment: Group 1 received glucocorticoids or no drugs, group 2 received nonbiologic immunosuppressive drugs (excluding JAK inhibitors) with or without glucocorticoids, and group 3 received JAK inhibitors or biologic drugs with or without nonbiologic immunosuppressives or glucocorticoids. TAKEAWAY: All patients presented with at least three clinical manifestations of RP, with a median of 11 manifestations per patient; all showed ear, nose, or airway involvement, and 83% had musculoskeletal manifestations. A substantial portion of patients (41%) developed organ damage, including sensorineural hearing loss (25%), auricular and saddle nose deformities (12% each), and subglottic stenosis (9%); among those who underwent dynamic CT of the chest, 31% had tracheomalacia, and 20% had bronchomalacia. Treatment groups 1, 2, and 3 comprised 19%, 28%, and 53% of patients, respectively; most patients (95%) received glucocorticoids, and a substantial proportion (81%) received additional immunomodulatory treatments. Patients in treatment group 3 had the highest rate of organ damage (62% vs 22% in group 2 and 15% in group 1) and were more likely to have arthritis and stenosis, whereas those in group 1 were less likely to experience nose pain. IN PRACTICE: 'Standardized assessment of disease activity is warranted for patients with RP for early detection and timely initiation of treatment. These findings also highlight the absence of a consensus approach to treatment for patients with RP and underscore the need for clinical trials and treatment guidelines in this disease to help reduce the enormous burden of disease for patients,' the authors wrote. SOURCE: This study was led by Roger Yang, MD, University of Pennsylvania, Philadelphia, and University of Montreal, Montreal, Quebec, Canada. It was published online on May 20, 2025, in ACR Open Rheumatology . LIMITATIONS: This study did not capture data on dose and duration of immunomodulatory medications or clinical features at treatment decisions. Treatment choices were made independently by clinicians and may have been influenced by factors such as drug availability or insurance, introducing variability. Moreover, the academic referral setting may have contributed to selection bias. DISCLOSURES: Two authors reported receiving support from the Vasculitis Clinical Research Consortium, Association des médecins rhumatologues du Québec, Institute for Translational Medicine and Therapeutics, and other sources. This research was also supported by the Relapsing Polychondritis Foundation and other generous donors to the Penn Relapsing Polychondritis Program.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store